{
  "id": "dc17d6e58c34d2e6",
  "title": "STAT+: Kymera drug positioned to rival Sanofi and Regeneron\u2019s Dupixent succeeds in early-stage eczema trial",
  "description": "Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.",
  "content": "Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2025/12/08/kymera-kt-621-clinical-trial-results-atopic-dermatitis-challenge-dupixent/?utm_campaign=rss",
  "published_at": "2025-12-08T12:00:00+00:00",
  "fetched_at": "2025-12-09T00:22:19.510482+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug",
    "ai"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: Kymera drug positioned to rival Sanofi and Regeneron\u2019s Dupixent succeeds in early-stage eczema trial",
    "description": "Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.",
    "url": "https://www.statnews.com/2025/12/08/kymera-kt-621-clinical-trial-results-atopic-dermatitis-challenge-dupixent/?utm_campaign=rss",
    "published": "2025-12-08T12:00:00+00:00",
    "source": "STAT"
  }
}